Bioventus Inc. · NASDAQ:BVS
Bioventus — Canaccord Genuity Global Growth Conference 2023
11 slides from Bioventus's conference presentation, August 2023
Slide 1: Innovations for Active Healing
INNOVATIONS FOR ACTIVE HEALING Canaccord Genuity Global Mark Singleton Growth Conference Chief Financial Officer August 2023
Slide 2: Forward-Looking Statements
Innovations For Active Healing Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentati
Slide 3: Bioventus Today
Innovations For Active Healing Bioventus Today MARKET LEADERSHIP INNOVATION & DEVELOPMENT VALUE CREATION $511M1 LTM Global Revenue 50%3 of +11% CAGR² Surgical Strong Revenue Solutions Revenue from Pain Products Momentum Treatments Launched 2016-2022 since 2018 Restorative Therapies Diverse Portfolio
Slide 4: Our Transformational Journey
Innovations For Active Healing OUR TRANSFORMATIONAL JOURNEY 2012-2015 2016-2020 2021 and Beyond Establishing Strong Diversifying with Positioning Portfolio Foundation Innovation for Long Term Growth • Entered US licensing • Completed IPO • Formed Standalone Company agreement for Gelsyn • Acquired Bi
Slide 5: Strategic Building Blocks for Growth as Category Leader
Innovations For Active Healing Strategic Building Blocks for Growth as Category Leader Positioned to Benefit from Favorable Demographics and Tailwinds Across Call Points Pain Treatments Restorative Therapies Surgical Solutions General Spine Neurosurgeon Sports Medicine Foot & Ankle Orthopedic Foot &
Slide 6: Expanding Addressable Market and Accelerating Growth with Recent M&A
Innovations For Active Healing Expanding Addressable Market and Accelerating Growth with Recent M&A Surgical Solutions Pain Treatments Surgical Solutions Pain Treatments ~3x Increase in TAM $4.5B Bioness and Misonix $14.8B 2016 TAM 2023 TAM Acquisitions Restorative Therapies Restorative Therapies 6
Slide 7: Diversified Portfolio Driving Growth Through Innovation and Market Development
Innovations For Active Healing Diversified Portfolio Driving Growth Through Innovation and Market Development Portfolio Diversification New Product1 Revenue as % of Revenue2 60.0% 50.0% Only 25% of 40.0% Revenue from Elective Surgical 30.0% Procedures 20.0% 10.0% 0.0% Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q
Slide 8: 2023 Sales Growth Limited Due to HA Headwinds
Innovations For Active Healing 2023 Sales Growth Limited Due to HA Headwinds $ millions Revenue for First Six Future Tailwinds Current Headwinds Months of 2023 Revenue declined 1% for the first Revenue growth expected to re- $258 $256 six months of 2023 accelerate in 2024 HA revenue declined due to
Slide 9: Significant Increase in Adjusted EBITDA in First Six Months of 2023
Innovations For Active Healing Significant Increase in Adjusted EBITDA in First Six Months of 2023 $ millions Adjusted EBITDA for First Six Months of 2023 Increased Adjusted EBITDA by more the $45 50% in first six months of 2023 $30 Initiated restructuring at the end of 2022 generating $10 million o
Slide 10: Substantial Improvement in Net Leverage Ratio
Innovations For Active Healing Substantial Improvement in Net Leverage Ratio Net Leverage Ratio1 Amended credit agreement with bank 5.50 partners in March which provides 20% cushion to target metrics through Q1 4.33 2024 Reduced Term Loan and Revolver borrowings by $60 million in second quarter Proc
Slide 11: Bioventus: A Compelling Investment Opportunity
Innovations For Active Healing BIOVENTUS: A COMPELLING INVESTMENT OPPORTUNITY Re-accelerating Revenue Starting in 2024 Diversified Portfolio of Current and Future Growth Drivers Expanding Operating Margins from Growth and Disciplined Investment Reducing Debt and Increasing Cash Flow Generation
Bioventus — Canaccord Genuity Global Growth Conference 2023 on 6ix